|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4980286A
(en)
|
1985-07-05 |
1990-12-25 |
Whitehead Institute For Biomedical Research |
In vivo introduction and expression of foreign genetic material in epithelial cells
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
US5525491A
(en)
|
1991-02-27 |
1996-06-11 |
Creative Biomolecules, Inc. |
Serine-rich peptide linkers
|
|
US5262522A
(en)
|
1991-11-22 |
1993-11-16 |
Immunex Corporation |
Receptor for oncostatin M and leukemia inhibitory factor
|
|
AU3830895A
(en)
|
1994-10-07 |
1996-05-02 |
Amgen Boulder Inc. |
Dimeric il-4 inhibitors
|
|
AUPN477695A0
(en)
|
1995-08-14 |
1995-09-07 |
Commonwealth Scientific And Industrial Research Organisation |
Gene therapy
|
|
GB9626029D0
(en)
|
1996-12-14 |
1997-01-29 |
Univ Leeds |
EVH-1 vectors
|
|
US5998598A
(en)
|
1997-03-10 |
1999-12-07 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Immunoadhesins and methods of production and use thereof
|
|
EP0975771B1
(en)
|
1997-04-18 |
2007-07-11 |
Biogen Idec MA Inc. |
Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins
|
|
AU4572899A
(en)
|
1998-06-16 |
2000-01-05 |
Biogen, Inc. |
Variant type ii tgf-beta receptor fusion proteins and methods
|
|
US6472179B2
(en)
|
1998-09-25 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Receptor based antagonists and methods of making and using
|
|
US7083950B2
(en)
|
1998-09-25 |
2006-08-01 |
Regeneron Pharmaceuticals, Inc. |
High affinity fusion proteins and therapeutic and diagnostic methods for use
|
|
EP1200124B1
(en)
|
1999-07-13 |
2008-09-10 |
Bolder Biotechnology, Inc. |
Erythropoietin-immunoglobulin fusion proteins
|
|
WO2001010912A1
(en)
|
1999-08-09 |
2001-02-15 |
Lexigen Pharmaceuticals Corp. |
Multiple cytokine-antibody complexes
|
|
US7638604B2
(en)
|
2001-02-23 |
2009-12-29 |
Genetics Institute, Llc |
Monoclonal antibodies against interleukin-22
|
|
US20030125251A1
(en)
|
2001-06-21 |
2003-07-03 |
Wakefield Lalage M. |
Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta
|
|
AU2003215136A1
(en)
*
|
2002-02-08 |
2003-09-02 |
University Of Medicine And Dentistry Of New Jersey |
Ifn-a/b-independent mechanism of antiviral protection
|
|
WO2005028517A2
(en)
|
2003-05-09 |
2005-03-31 |
The General Hospital Corporation |
SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
|
|
WO2005024027A1
(ja)
|
2003-09-02 |
2005-03-17 |
National Institute Of Advanced Industrial Science And Technology |
抗体医薬
|
|
US20090155267A1
(en)
*
|
2005-02-09 |
2009-06-18 |
Apollo Life Sciences Limited |
Molecule and chimeric molecules thereof
|
|
CN101146825A
(zh)
*
|
2005-02-14 |
2008-03-19 |
阿波罗生命科学有限公司 |
分子及其嵌合分子
|
|
JP2008536477A
(ja)
|
2005-02-14 |
2008-09-11 |
アポロ ライフ サイエンシズ リミテッド |
分子およびそのキメラ分子
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US20090175819A1
(en)
*
|
2005-11-15 |
2009-07-09 |
Apollo Life Sciences Limited |
Molecule and chimeric molecules thereof
|
|
CA2687377C
(en)
|
2007-05-30 |
2013-05-14 |
Genexine Co., Ltd. |
Immunoglobulin fusion proteins
|
|
WO2008157367A1
(en)
|
2007-06-15 |
2008-12-24 |
Genzyme Corporation |
Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
|
|
US8420784B2
(en)
*
|
2008-05-27 |
2013-04-16 |
Kyowa Hakko Kirin Co., Ltd. |
Interleukin 10 receptor, (IL-10R) antibodies
|
|
JP2011526794A
(ja)
|
2008-07-02 |
2011-10-20 |
エマージェント プロダクト デベロップメント シアトル， エルエルシー |
ＴＧＦ−βアンタゴニスト多重標的結合性分子
|
|
EP2326670A4
(en)
|
2008-09-17 |
2014-04-16 |
Nat Res Council Canada |
HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY
|
|
DK3029144T3
(da)
|
2009-03-02 |
2019-10-21 |
Univ California |
Tumorselektive adenovirus e1a- og e1b-mutanter
|
|
US8993524B2
(en)
|
2010-03-05 |
2015-03-31 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
EP3333183B1
(en)
|
2012-04-30 |
2023-02-22 |
Biocon Limited |
Targeted/immunomodulatory fusion proteins and methods for making same
|
|
CA3081073C
(en)
|
2013-03-12 |
2023-09-12 |
Biocon Ltd. |
Fusion immunomodulatory proteins and methods for making same
|
|
HK1225742A1
(zh)
|
2013-08-22 |
2017-09-15 |
Acceleron Pharma, Inc. |
TGF-β受体II型变体及其用途
|
|
EP4005585B1
(en)
|
2013-11-21 |
2024-03-27 |
The Brigham & Women's Hospital, Inc. |
Compositions and methods for treating right ventricular hypertrophy
|
|
JP6731346B2
(ja)
|
2014-02-10 |
2020-07-29 |
メルク パテント ゲーエムベーハー |
標的ＴＧＦβ阻害
|
|
EP3233920B1
(en)
|
2014-12-19 |
2020-08-26 |
Alkermes, Inc. |
Single chain fc fusion proteins
|
|
EP3288965B1
(en)
*
|
2015-04-29 |
2019-06-26 |
Mediolanum Farmaceutici S.p.A. |
A soluble chimeric interleukin-10 receptor and therapeutic use thereof
|
|
CA2996996A1
(en)
|
2015-08-31 |
2017-03-09 |
National Research Council Of Canada |
Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
|
|
AU2017336546C1
(en)
|
2016-09-27 |
2025-05-29 |
Epicentrx, Inc. |
Immunomodulatory fusion proteins
|
|
US10232053B2
(en)
*
|
2016-12-30 |
2019-03-19 |
Trieza Therapeutics, Inc. |
Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
|